Evaluation of the diagnostic concordance of FDA-approved PD-L1 assays in clear cell renal cell carcinoma

Abstract Therapeutic strategies for advanced renal cell carcinoma have advanced dramatically since the approval of immune checkpoint inhibitors. To date, four PD-L1 assays have been established as companion diagnostic tools for checkpoint inhibitors. However, all PD-L1 assays present several limitat...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Yoko Koh, Taigo Kato, Gaku Yamamichi, Eisuke Tomiyama, Makoto Matsushita, Koji Hatano, Atsunari Kawashima, Norio Nonomura, Motohide Uemura
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Nature Portfolio 2025-07-01
Sarja:	Scientific Reports
Aiheet:	Clear cell renal cell carcinoma Programed death-ligand 1 (PD-L1) Immunohistochemistry Next-generation sequencing Companion diagnostics
Linkit:	https://doi.org/10.1038/s41598-025-05697-4
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!